ICML 2019 | Recent publication on the impact of response to lymphodepletion on PFS in NHL
Alexandre Hirayama
Alexandre Hirayama, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, discusses his recent research into the impact of response to lymphodepletion on PFS in non-Hodgkin lymphoma (NHL). This revealed that LDH, MCP-1, and IL-7 are independently associated with PFS in patients with aggressive NHL after CD19 CAR T-cell therapy. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.
Related videos

Venetoclax monotherapy for relapsed/refractory Waldenström’s macroglobulinemia
Jorge Castillo

Waldenström's PFS unaffected by ibrutinib dose reduction, for now
Jorge Castillo

Anti-CD19 CAR T-cell therapy in combination with ibrutinib for CLL/SLL
Saar Gill

Waldenström’s macroglobulinemia: a link between institution visited and survival
Stephen Ansell

Evaluation of systemic immunity in cHL via single cell cytokine secretion technology
Catherine Diefenbach
More from Alexandre Hirayama